Eurand Names Bill Newbould Vice President, Investor Relations

Corporate news announcement processed and transmitted by Hugin ASA.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

PHILADELPHIA, July 10, 2008 (PRIME NEWSWIRE) -- Eurand N.V.
(Nasdaq:EURX), a specialty pharmaceutical company that develops,
manufactures and commercializes enhanced pharmaceutical and
biopharmaceutical products based on its proprietary drug formulation
technologies, today announced the appointment of A. William (Bill)
Newbould to the newly created position of Vice President, Investor
Relations. Reporting directly to Eurand's Chief Executive Officer
Gearoid Faherty, Newbould will be responsible for developing and
implementing the Company's investor relations program. He will be
based in Eurand's Yardley, Pennsylvania, office.

"I am delighted to welcome Bill Newbould to the Eurand team," Faherty
said. "Having served more than 20 years as an investor relations
executive, including the last 11 in positions of increasing
responsibility in the specialty pharmaceutical and biotech
industries, he brings an extensive network of contacts and a wealth
of experience to an area that is becoming an increasingly important
component of Eurand's growth."

Previously, Newbould was Vice President, Corporate Communications, at
Endo Pharmaceuticals Inc., a specialty pharmaceuticals company where
he was responsible for investor and media relations, product
communications and public relations. Prior to joining Endo, he was
Director, Corporate Communications, for Centocor, Inc., a Johnson &
Johnson subsidiary, which he joined in 1997 as Manager, Investor
Relations. His career also includes investor relations experience in
the water utility and financial services industries.

Newbould received a bachelor's degree from Gettysburg College and
completed course work at Fairfield University's Graduate School of
Corporate and Political Communication. He is a member of the National
Investor Relations Institute (NIRI) and the Greater Philadelphia
Senior Executives Group.

About Eurand

Eurand is a specialty pharmaceutical company that develops,
manufactures and commercializes enhanced pharmaceutical and
biopharmaceutical products based on its proprietary drug formulation
technologies. Eurand has had four partnered products approved by the
FDA since 2001 and has a pipeline of product candidates in
development for itself and its collaboration partners. Eurand
completed two phase III clinical trials for EUR-1008 (Zentase),
intended for the treatment of Exocrine Pancreatic Insufficiency and,
as announced on June 18, 2008, received an approvable letter from the
FDA for its NDA for this product. Eurand's technology platforms
include bioavailability enhancement of poorly soluble drugs,
customized release, taste-masking/fast-dissolving formulations and
drug conjugation.

Eurand is a global company with facilities in the USA and Europe. For
more information, visit Eurand's website at www.eurand.com.

This release, and oral statements made with respect to information
contained in this release, constitutes forward-looking statements.
Such forward-looking statements include those which express plan,
anticipation, intent, contingency, goals, targets or future
development and/or otherwise are not statements of historical fact
including, but not limited to the future and status of our NDA filing
for EUR-1008, enrollment and future plans for our clinical trials,
progress of and reports of results from clinical studies, clinical
development plans and product development activities. The words
"potentially", "anticipates", "could", "calls for" and similar
expressions also identify forward-looking statements. These
statements are based upon management's current expectations and are
subject to risks and uncertainties, known and unknown, which could
cause actual results and developments to differ materially from those
expressed or implied in such statements. Factors that could affect
actual results include risks associated with the possibility that the
FDA does not approve our NDA or continues to delay approval; the
outcome of any discussions with the FDA; and unexpected delays or
additional requirements in preparation of materials for submission to
the FDA as a part of our NDA filing. Forward-looking statements
contained in this press release are made as of this date, and we
undertake no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise. Actual events could differ materially from those
anticipated in the forward-looking statements.

CONTACT: Eurand N.V.
Bill Newbould, Vice President, Investor Relations
+1 267-759-9400

The Ruth Group
Nick Laudico
+1 646-536-7030
nlaudico@theruthgroup.com
Sara Ephraim
+1 646-536-7002
sephraim@theruthgroup.com

--- End of Message ---

Eurand N.V.
845 Center Drive Vandalia, Ohio USA

WKN: A0MSPK; ISIN:
NL0000886448;
;
Copyright © Hugin AS 2008. All rights reserved.